Giuseppe Boriani,, Fehra, Fesc

List of Publications by Year
in descending order

719 papers	40,328 citations	5268 83 h-index	4015 176 g-index
745 all docs	745 docs citations	745 times ranked	23704 citing authors

#	Article	IF	Citations
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
2	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.2	2,176
3	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	2.2	1,576
4	Efficacy of Implantable Cardioverterâ€“Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2000, 342, 365-373.	27.0	953
5	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118.	1.7	908
6	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	2.2	899
7	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.8	718
8	Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2007, 298, 405-12.	7.4	705
9	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	1.7	635
10	European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal, 2018, 39, 508-579.	2.2	595
11	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	1.7	494
12	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	2.2	490
13	Screening for Atrial Fibrillation. Circulation, 2017, 135, 1851-1867.	1.6	453
14	Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. Journal of the American College of Cardiology, 2005, 46, 1913-1920.	2.8	375
15	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	1.7	370
16	Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	2.2	347
17	Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events. Journal of Cardiovascular Electrophysiology, 2009, 20, 241-248.	1.7	341
18	Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia. Circulation, 2010, 122, 1144-1152.	1.6	272

#	Article	IF	Citations
19	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. American Heart Journal, 2017, 189, 137-145.	2.7	258
20	The Changing Landscape for StrokeÂPrevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	2.8	244
21	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Europace, 2018, 20, 1217-1217.	1.7	243
22	Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. American Journal of Medicine, 2015, 128, 509-518.e2.	1.5	242
23	Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2013, 61, 1527-1535.	2.8	240
24	Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. American Journal of Cardiology, 1992, 70, 69-72.	1.6	239
25	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2016, 17, 355-383.	1.2	233
26	Left Superior Vena Cava Persistence in Patients Undergoing Pacemaker or Cardioverter-Defibrillator Implantation. Chest, 2001, 120, 139-144.	0.8	224
27	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€"endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).	1.7	216
28	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLAECE). Europace, 2017, 19, 1589-1623.	1.7	208
29	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq1 1 0.784314 rgBT /Over	2.3	208
30	Dilated-Hypokinetic Evolution of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 1543-1550.	2.8	199
31	Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart, 2007, 93, 65-71.	2.9	198
32	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, 2018, 20, 1231-1242.	1.7	194
33	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2012, 14, 8-27.	1.7	193
34	Device-detected subclinical atrial tachyarrhythmias: definition, implications and managementâ€"an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 1556-1578.	1.7	186
35	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal, 2018, 39, 2314-2325.	2.2	186
36	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184

#	Article	IF	Citations
37	Improving Stroke Risk Stratification Using the CHADS ₂ and CHA ₂ DS ₂ -VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring. Stroke, 2011, 42, 1768-1770.	2.0	176
38	Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. American Journal of Cardiology, 1994, 74, 503-505.	1.6	175
39	Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. American Heart Journal, 2006, 151, 1050-1058.	2.7	169
40	Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MOREâ€CARE multicentre randomized controlled trial. European Journal of Heart Failure, 2017, 19, 416-425.	7.1	165
41	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015, 17, 24-31.	1.7	164
42	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2015, 17, 1197-1214.	1.7	160
43	Clinical Relevance of Atrial Fibrillation/Flutter, Stroke, Pacemaker Implant, and Heart Failure in Emery-Dreifuss Muscular Dystrophy. Stroke, 2003, 34, 901-908.	2.0	158
44	Randomized crossover comparison of right atrial appendage pacing versus interatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. American Heart Journal, 2001, 142, 1047-1055.	2.7	150
45	A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. European Heart Journal, 2009, 30, 2758-2767.	2.2	149
46	Dynamic Electrophysiological Behavior of Human Atria During Paroxysmal Atrial Fibrillation. Circulation, 1995, 92, 1193-1202.	1.6	148
47	Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 500-507.	4.1	147
48	Oral Propafenone To Convert Recent-Onset Atrial Fibrillation in Patients with and without Underlying Heart Disease. Annals of Internal Medicine, 1997, 126, 621.	3.9	145
49	â€˜Real-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. American Journal of Medicine, 2014, 127, 519-529.e1.	1.5	144
50	Antiarrhythmic drugsâ€"clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace, 2018, 20, 731-732an.	1.7	144
51	Reducing Unnecessary Right Ventricular Pacing with the Managed Ventricular Pacing Mode in Patients with Sinus Node Disease and AV Block. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 697-705.	1.2	140
52	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196.	1.7	138
53	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	1.7	135
54	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace, 2015, 17, 1777-1786.	1.7	128

#	Article	IF	Citations
55	Worldwide Survey of COVID-19â€“Associated Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009458.	4.8	127
56	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. , 2010, 125, 196-218.		126
57	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2013, 15, 1540-1556.	1.7	125
58	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 891-911.	1.7	124
59	A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. International Journal of Cardiology, 1994, 43, 305-313.	1.7	121
60	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	1.7	121
61	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€"endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	2.2	120
62	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2015, 17, 1747-1769.	1.7	119
63	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n Cardiaca y Electrofisiologia (SOLAECE). Europace, 2017, 19, 465-511.	1.7	118
64	Contemporary stroke prevention strategies in 11â€‰096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace, 2018, 20, 747-757.	1.7	118
65	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thrombosis and Haemostasis, 2021, 121, 270-278.	3.4	118
66	Device-Detected Atrial Tachyarrhythmias Predict Adverse Outcome in Real-World Patients With Implantable Biventricular Defibrillators. Journal of the American College of Cardiology, 2011, 57, 167-172.	2.8	116
67	Phrenic Stimulation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 402-410.	4.8	114
68	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. European Heart Journal, 2014, 35, 2352-2362.	2.2	111
69	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€"endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. European Journal of Cardio-thoracic Surgery, 2020, 57, e1-e31.	1.4	111
70	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 637-642.	2.8	107
71	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y. Europace, 2017, 19, 1757-1758.	1.7	107
72	How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace, 2022, 24, 979-1005.	1.7	107

#	Article	IF	Citations
73	Propafenone for Conversion of Recent-Onset Atrial Fibrillation. Chest, 1995, 108, 355-358.	0.8	106
74	Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management. Europace, 2010, 12, 1673-1690.	1.7	105
75	Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. European Heart Journal, 2004, 25, 1237-1241.	2.2	101
76	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	7.1	101
77	Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a metaâ€analysis of randomized controlled trials in patients with heart failure. European Journal of Heart Failure, 2016, 18, 195-204.	7.1	100
78	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nature Reviews Cardiology, 2017, 14, 701-714.	13.7	98
79	Closed loop stimulation in prevention of vasovagal syncope. Inotropy controlled pacing in vasovagal syncope (INVASY): a multicentre randomized, single blind, controlled study. Europace, 2004, 6, 538-547.	1.7	97
80	Antiarrhythmic Effect of Reverse Ventricular Remodeling Induced by Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2008, 52, 1442-1449.	2.8	96
81	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
82	Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 1727-1731.	1.6	93
83	Conversion of Recent-Onset Atrial Fibrillation to Sinus Rhythm: Effects of Different Drug Protocols. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2470-2474.	1.2	88
84	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1541-1550.	2.2	88
85	Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm, 2018, 15, 376-383.	0.7	86
86	The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systemsThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 893-894.	2.2	85
87	A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: The Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. American Heart Journal, 2010, 159, 1052-1058.e1.	2.7	85
88	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. European Heart Journal, 2013, 34, 1869-1874.	2.2	85
89	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). European Journal of Preventive Cardiology, 2017, 24, 4-40.	1.8	83
90	The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring. Journal of Medical Internet Research, 2013, 15, e167.	4.3	83

#	Article	IF	Citations
91	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Thrombosis and Haemostasis, 2011, 106, 1012-1019..	3.4	81
92	Long-Term Complications Related to Biventricular Defibrillator Implantation. Circulation, 2011, 123, 2526-2535.	1.6	80
93	First prospective, multi-centre clinical experience with a novel left ventricular quadripolar lead. Europace, 2012, 14, 365-372.	1.7	79
94	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	6.4	79
95	108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13â€“15 September 2002, Naarden, The Netherlands. Neuromuscular Disorders, 2003, 13, 508-515.	0.6	78
96	From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. Expert Review of Medical Devices, 2013, 10, 551-573.	2.8	78
97	Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace, 2009, 11, 716-726.	1.7	74
98	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace, 2021, 23, 174-183.	1.7	74
99	Pharmacological Cardioversion of Atrial Fibrillation. Drugs, 2004, 64, 2741-2762.	10.9	73
100	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	1.7	72
101	Impact of consistent atrial pacing algorithm on premature atrial complexe number and paroxysmal atrial fibrillation recurrences in brady-tachy syndrome: a randomized prospective cross over study. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 33-44.	1.3	70
102	Heart Transplantation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 387-392.	1.6	70
103	Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. International Journal of Cardiology, 1997, 58, 55-61.	1.7	69
104	Heart failure in patients with atrial fibrillation in Europe: a report from the <scp>EURObservational</scp> Research Programme Pilot survey on Atrial Fibrillation. European Journal of Heart Failure, 2015, 17, 570-582.	7.1	68
105	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Europace, 2019, 21, 844-845.	1.7	68
106	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2017, 19, euw242.	1.7	67
107	Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. Cardiovascular Research, 2021, 117, 1-21.	3.8	67
108	Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascular Pharmacology, 2016, 83, 26-35.	2.1	66

#	Article	IF	Citations
109	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clinic Proceedings, 2019, 94, 2427-2436.	3.0	66
110	Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). Internal and Emergency Medicine, 2020, 15, 1445-1456.	2.0	66
111	The wearable cardioverter-defibrillator: current technology and evolving indications. Europace, 2017, 19, 335-345.	1.7	65
112	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. Circulation, 2022, 145, 392-409.	1.6	65
113	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Tj ETQq1 1 0.784314 rgBT /Over	0.7	63
114	New devices in heart failure: an European Heart Rhythm Association report: Developed by the European Heart Rhythm Association; Endorsed by the Heart Failure Association. Europace, 2014, 16, 109-128.	1.7	62
115	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. European Journal of Internal Medicine, 2020, 77, 158-160.	2.2	62
116	Effects of Cardiac Resynchronization Therapy on Left Ventricular Twist. Journal of the American College of Cardiology, 2009, 54, 1317-1325.	2.8	61
117	â€˜Real-worldâ€™ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programmeâ€“Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace, 2016, 18, 648.1-657.	1.7	61
118	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace, 2019, 21, 1603-1604.	1.7	61
119	Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset. International Journal of Cardiology, 1992, 36, 87-93.	1.7	59
120	Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. Journal of the American College of Cardiology, 1999, 33, 333-341.	2.8	57
121	Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy. International Journal of Cardiology, 2018, 255, 175-183.	1.7	57
122	Electrophysiologic Manifestations of Ventricular Tachyarrhythmias Provoking Appropriate Defibrillator Interventions in High-Risk Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2007, 18, 483-487.	1.7	56
123	New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial. Heart Rhythm, 2015, 12, 1717-1725.	0.7	56
124	Role of ventricular autocapture function in increasing longevity of DDDR pacemakers: a prospective study. Europace, 2006, 8, 216-220.	1.7	55
125	Effects of cardiac resynchronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction. Heart, 2011, 97, 295-300.	2.9	55
126	â€˜Real-worldâ€™ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace, 2016, 19, euw112.	1.7	55

#	Article	IF	Citations
127	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	1.7	55
128	Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. Journal of Heart and Lung Transplantation, 2002, 21, 899-901.	0.6	54
129	P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion. International Journal of Cardiology, 2005, 101, 355-361.	1.7	54
130	2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 58.	0.6	54
131	Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems. Europace, 2008, 10, 1288-1295.	1.7	53
132	Clinical implications of left superior vena cava persistence in candidates for pacemaker or cardioverter-defibrillator implantation. Heart and Vessels, 2009, 24, 142-146.	1.2	53
133	Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 868-876.	7.1	53
134	AF burden is important - fact or fiction?. International Journal of Clinical Practice, 2014, 68, 444-452.	1.7	53
135	Age-Related Differences in Presentation, Treatment, and Outcome of Patients WithÂAtrial Fibrillation in Europe. JACC: Clinical Electrophysiology, 2015, 1, 326-334.	3.2	52
136	Exercise stress echocardiography is superior to rest echocardiography in predicting left ventricular reverse remodelling and functional improvement after cardiac resynchronization therapy. European Heart Journal, 2008, 30, 89-97.	2.2	51
137	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Scientific Reports, 2016, 6, 30271.	3.3	51
138	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. European Journal of Internal Medicine, 2018, 55, 28-34.	2.2	51
139	Telecardiology and Remote Monitoring of Implanted Electrical Devices: The Potential for Fresh Clinical Care Perspectives. Journal of General Internal Medicine, 2008, 23, 73-77.	2.6	50
140	A Prospective Randomized Evaluation of VV Delay Optimization in CRT-D Recipients: Echocardiographic Observations from the RHYTHM II ICD Study. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S120-S125.	1.2	50
141	Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace, 2011, 13, ii59-ii65.	1.7	50
142	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLEACE). European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 235-250.	3.0	50
143	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005820.	4.8	50
144	Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. American Heart Journal, 1996, 131, 1214-1216.	2.7	49

#	Article	IF	Citations
145	Cardiac Resynchronization Therapy: Variations in Echo-Guided Optimized Atrioventricular and Interventricular Delays During Follow-Up. Echocardiography, 2007, 24, 933-939.	0.9	49
146	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 643-648.	2.8	49
147	Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. Heart, 2010, 96, 546-549.	2.9	49
148	Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. Europace, 2019, 21, 1270-1279.	1.7	49
149	Efficacy and Tolerability in Fully Conscious Patients of Transvenous Low-Energy Internal Atrial Cardioversion for Atrial Fibrillation. American Journal of Cardiology, 1998, 81, 241-244.	1.6	48
150	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. Canadian Journal of Cardiology, 2019, 35, 619-633.	1.7	48
151	Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. Ageing Research Reviews, 2022, 79, 101652.	10.9	48
152	Actual Pacemaker Longevity: The Benefit of Stimulation by Automatic Capture Verification. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 873-881.	1.2	47
153	From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverterâ€“defibrillator systems. Expert Review of Medical Devices, 2011, 8, 235-255.	2.8	47
154	Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. Europace, 2013, 15, 1453-1462.	1.7	47
155	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace, 2017, 19, 1439-1448.	1.7	47
156	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace, 2019, 21, 1013-1022.	1.7	47
157	A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. European Heart Journal, 2001, 22, 2180-2191.	2.2	46
158	Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm Association (EHRA). Europace, 2014, 16, i1-i78.	1.7	46
159	Metaâ€analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on allâ€cause mortality and hospitalizations. European Journal of Heart Failure, 2012, 14, 652-660.	7.1	45
160	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 432-439.	1.6	45
161	Cardiac device therapy in patients with left ventricular dysfunction and heart failure: â€˜realâ€worldâ€™ data on longâ€term outcomes (mortality, hospitalizations, days alive and out of hospital). European Journal of Heart Failure, 2016, 18, 693-702.	7.1	45
162	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 194-205.	6.4	45

#	Article	IF	Citations
163	Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Circulation, 2004, 110, e438-42.	1.6	44
164	Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. Peptides, 2006, 27, 1776-1786.	2.4	44
165	Interventricular Delay Interval Optimization in Cardiac Resynchronization Therapy Guided by Echocardiography Versus Guided by Electrocardiographic QRS Interval Width. American Journal of Cardiology, 2008, 102, 1373-1377.	1.6	44
166	Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review. Health Policy, 2016, 120, 1-15.	3.0	44
167	Predictors of long-term survival free from relapses after extraction of infected CIED. Europace, 2018, 20, 1018-1027.	1.7	43
168	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	1.5	43
169	Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Internal and Emergency Medicine, 2020, 15, 1573-1576.	2.0	43
170	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460.	2.2	43
171	Benefits in Projected Pacemaker Longevity and in Pacing Related Costs Conferred by Automatic Threshold Tracking. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1783-1787.	1.2	42
172	Evaluation of Myocardial Injury Following Repeated Internal Atrial Shocks by Monitoring Serum Cardiac Troponin I Levels. Chest, 2000, 118, 342-347.	0.8	42
173	Combined Use of Morphology Discrimination, Sudden Onset, and Stability as Discriminating Algorithms in Single Chamber Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1357-1366.	1.2	42
174	Left Ventricular Rotational Mechanics in Acute Myocardial Infarction and in Chronic (Ischemic and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	41
175	Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the <scp>VALIDâ€CRT</scp> risk score. European Journal of Heart Failure, 2015, 17, 717-724.	7.1	41
176	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2015, 17, 194-206.	1.7	41
177	Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236.	3.4	41
178	Impact of Cardiac Implantable Electronic Device Infection. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008280.	4.8	41
179	Cardiac resynchronization by pacing: an electrical treatment of heart failure. International Journal of Cardiology, 2004, 94, 151-161.	1.7	40
180	Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome. International Journal of Clinical Practice, 2007, 61, 748-756.	1.7	40

#	Article	IF	Citations
181	EHRA White Paper: knowledge gaps in arrhythmia managementâ€"status 2019. Europace, 2019, 21, 993-994.	1.7	40
182	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. European Journal of Internal Medicine, 2021, 86, 1-11.	2.2	40
183	Rate Control in Atrial Fibrillation. Drugs, 2003, 63, 1489-1509.	10.9	39
184	Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverterâ€defibrillator therapies and hospitalizations. European Journal of Heart Failure, 2018, 20, 1472-1481.	7.1	39
185	Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008503.	4.8	39
186	Sudden cardiac death in dialysis patients: different causes and management strategies. Nephrology Dialysis Transplantation, 2021, 36, 396-405.	0.7	39
187	Evaluation by Cardiopulmonary Exercise Test of DDDR Versus DDD Pacing. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1908-1913.	1.2	38
188	Paroxysmal Atrial Fibrillation in Sleep. Sleep, 1997, 20, 396-398.	1.1	38
189	The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology. Europace, 2013, 15, 927-936.	1.7	38
190	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. American Heart Journal, 2016, 181, 83-91.	2.7	38
191	Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD). Heart Rhythm, 2016, 13, 1987-1992.	0.7	38
192	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. European Journal of Internal Medicine, 2020, 82, 97-104.	2.2	38
193	Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart, 2021, 107, 1630-1636.	2.9	38
194	Comparison of Two Strategies to Reduce Ventricular Pacing in Pacemaker Patients. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 167-176.	1.2	37
195	Transcatheter aortic valve implantation with a selfâ€expanding nitinol bioprosthesis. Catheterization and Cardiovascular Interventions, 2012, 79, 712-719.	1.7	37
196	Cardiac Resynchronization Therapy WithÂaÂQuadripolar Electrode Lead Decreases Complications at 6 Months. JACC: Clinical Electrophysiology, 2016, 2, 212-220.	3.2	37
197	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncologyâ€"Part 1: acute coronary syndromes and acute pericardial diseases. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 947-959.	1.0	37
198	Cardiac resynchronization therapy during rest and exercise: comparison of two optimization methods. Europace, 2008, 10, 1161-1169.	1.7	36

#	Article	IF	Citations
199	In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: A population-based observational study. Lancet Regional Health - Europe, The, 2021, 3, 100055.	5.6	36
200	Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. American Heart Journal, 2003, 146, 298-303.	2.7	34
201	Prediction of atrial fibrillation in patients with an implantable cardioverterâ€defibrillator and heart failure. European Journal of Heart Failure, 2010, 12, 1101-1110.	7.1	34
202	P-wave Variability and Atrial Fibrillation. Scientific Reports, 2016, 6, 26799.	3.3	34
203	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. Journal of Clinical Medicine, 2021, 10, 3979.	2.4	34
204	Rhythm Discrimination by Rate Branch and QRS Morphology in Dual Chamber Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 466-470.	1.2	33
205	Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. Europace, 2011, 13, 1166-1173.	1.7	33
206	Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 182-188.	2.2	33
207	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. Europace, 2018, 20, 243-252.	1.7	33
208	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. European Journal of Preventive Cardiology, 2021, 28, 611-621.	1.8	33
209	The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: Rationale and design. American Heart Journal, 2010, 160, 42-48.	2.7	32
210	Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants. Pharmacoeconomics, 2013, 31, 971-980.	3.3	32
211	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace, 2017, 19, euw150.	1.7	32
212	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. European Heart Journal, 2021, 42, 3541-3554.	2.2	32
213	Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence A prospective, multicentre study. Europace, 1999, 1, 220-225.	1.7	31
214	Cost-effectiveness of cardiac resynchronisation therapy. Heart, 2012, 98, 1828-1836.	2.9	31
215	Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 172-179.	3.0	31
216	Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis. European Heart Journal Cardiovascular Imaging, 2018, 19, 654-659.	1.2	31

#	Article	IF	Citations
217	Atrial fibrillation prevention: an appraisal of current evidence. Heart, 2018, 104, 882-887.	2.9	31
218	Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. European Journal of Internal Medicine, 2019, 59, 27-33.	2.2	31
219	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. European Journal of Internal Medicine, 2021, 92, 100-106.	2.2	31
220	Temporal variability of atrial tachyarrhythmia burden in bradycardiaâ€“tachycardia syndrome patients. European Heart Journal, 2005, 26, 165-172.	2.2	30
221	Outcome of cardioverterâ€“defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. Heart and Vessels, 2007, 22, 184-192.	1.2	30
222	Comparison of the Usefulness of Cardiac Resynchronization Therapy in Three Age-Groups (<65, 65-74) Tj ETQq0 0 0 rgBT /Overlock 10 1510-1516.	1.6	30
223	Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. European Journal of Heart Failure, 2016, 18, 1060-1068.	7.1	30
224	The â€œSubtleâ€•connection between development of cardiac implantable electrical device infection and survival after complete system removal: An observational prospective multicenter study. International Journal of Cardiology, 2018, 250, 146-149.	1.7	30
225	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. International Journal of Cardiology, 2018, 271, 68-74.	1.7	30
226	Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. Journal of Clinical Medicine, 2021, 10, 729.	2.4	30
227	Cost-effectiveness of implantable cardioverter-defibrillators. European Heart Journal, 2001, 22, 990-996.	2.2	29
228	Electrocardiographic remodeling during cardiac resynchronization therapy. International Journal of Cardiology, 2006, 108, 165-170.	1.7	29
229	Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator. Europace, 2018, 20, e69-e77.	1.7	29
230	What do we do about atrial high rate episodes?. European Heart Journal Supplements, 2020, 22, O42-O52.	0.1	29
231	Remote monitoring and telemedicine in heart failure: implementation and benefits. Current Cardiology Reports, 2021, 23, 55.	2.9	29
232	Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?. Current Pharmaceutical Design, 2014, 21, 659-666.	1.9	29
233	Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. European Journal of Heart Failure, 2003, 5, 419-425.	7.1	28
234	Electrical storm in patients with biventricular implantable cardioverter defibrillator: Incidence, predictors, and prognostic implications. American Heart Journal, 2008, 156, 847-854.	2.7	28

#	Article	IF	Citations
235	Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). Europace, 2008, 11, 476-482.	1.7	28
236	Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable?. Europace, 2014, 16, 533-540.	1.7	28
237	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n Cardiaca y Electrofisiologia (SOLAECE). European Heart Journal, 2018, 39, ehw455.	2.2	28
238	Pacemaker-detected severe sleep apnea predicts new-onset atrial fibrillation. Europace, 2017, 19, 1937-1943.	1.7	28
239	Intrahospital organizational model of remote monitoring data sharing, for a global management of patients with cardiac implantable electronic devices: a document of the Italian Association of Arrhythmology and Cardiac Pacing. Journal of Cardiovascular Medicine, 2020, 21, 171-181.	1.5	28
240	Persistent Atrial Fibrillation Worsens Heart Rate Variability, Activity and Heart Rate, as Shown by a Continuous Monitoring by Implantable Biventricular Pacemakers in Heart Failure Patients. Journal of Cardiovascular Electrophysiology, 2008, 19, 693-701.	1.7	27
241	A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. American Heart Journal, 2008, 155, 100.e1-100.e9.	2.7	27
242	Impact of Time to Reperfusion After Acute Myocardial Infarction on Myocardial Damage Assessed by Left Ventricular Longitudinal Strain. American Journal of Cardiology, 2009, 104, 480-485.	1.6	27
243	Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. Journal of Cardiovascular Medicine, 2014, 15, 554-564.	1.5	27
244	Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA. Europace, 2018, 20, 1882-1897.	1.7	27
245	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. Europace, 2019, 21, 230-238.	1.7	27
246	Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. Internal and Emergency Medicine, 2021, 16, 1131-1140.	2.0	27
247	Seventeen-year trend (2001â€“2017) in pacemaker and implantable cardioverter-defibrillator utilization based on hospital discharge database data: An analysis by age groups. European Journal of Internal Medicine, 2021, 84, 38-45.	2.2	27
248	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Current Pharmaceutical Design, 2021, 27, 263-275.	1.9	27
249	Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. European Journal of Internal Medicine, 2022, 101, 1-7.	2.2	27
250	Propafenone in the Treatment of Cardiac Arrhythmias. Drug Safety, 1995, 12, 55-72.	3.2	26
251	Cardiac Resynchronization Therapy:. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S11-4.	1.2	26
252	Economic evaluation in cardiology. Europace, 2011, 13, ii3-ii8.	1.7	26

#	Article	IF	Citations
253	Management of atrial fibrillation in bradyarrhythmias. Nature Reviews Cardiology, 2015, 12, 337-349.	13.7	26
254	Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. Europace, 2017, 19, euw221.	1.7	26
255	Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD). Europace, 2018, 20, 979-985.	1.7	26
256	Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. European Journal of Preventive Cardiology, 2020, 27, 633-644.	1.8	26
257	Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry. International Journal of Cardiology, 2021, 323, 140-147.	1.7	26
258	Oral Loading with Propafenone for Conversion of Recent-Onset Atrial Fibrillation. Drugs, 2002, 62, 415-423.	10.9	25
259	Atrial Fibrillation Precipitating Sustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2002, 13, 954-954.	1.7	25
260	Atrial Tachyarrhythmia Recurrence Temporal Patterns in Bradycardia Patients Implanted with Antitachycardia Pacemakers. Journal of Cardiovascular Electrophysiology, 2004, 15, 44-51.	1.7	25
261	Implantable electrical devices for prevention of sudden cardiac death: data on implant rates from a 'real world' regional registry. Europace, 2010, 12, 1224-1230.	1.7	25
262	The EHRA White Book. Europace, 2012, 14, ii1-ii55.	1.7	25
263	Elevated TGF Î²2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. Nucleus, 2018, 9, 337-349.	2.2	25
264	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20Âyears. Internal and Emergency Medicine, 2020, 15, 1183-1192.	2.0	25
265	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clinical Research in Cardiology, 2022, 111, 70-84.	3.3	25
266	Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. Cardiovascular Drugs and Therapy, 1990, 4, 281-287.	2.6	24
267	Clinical Evaluation of Morphology Discrimination: An Algorithm for Rhythm Discrimination in Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 994-1001.	1.2	24
268	Far-Field R Wave Oversensing in Dual Chamber Pacemakers Designed for Atrial Arrhythmia Management:. Effect of Pacing Site and Lead Tip to Ring Distance. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1221-1230.	1.2	24
269	Short QT syndrome and arrhythmogenic cardiac diseases in the young: the challenge of implantable cardioverter-defibrillator therapy for children. European Heart Journal, 2006, 27, 2382-2384.	2.2	24
270	The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. American Heart Journal, 2008, 156, 445-451.	2.7	24

#	Article	IF	Citations
271	Investigating Regional Variation of Cardiac Implantable Electrical Device Implant Rates in European Healthcare Systems: What Drives Differences?. Health Economics (United Kingdom), 2017, 26, 30-45.	1.7	24
272	Physical Activity Measured by Implanted Devices Predicts Atrial Arrhythmias and Patient Outcome: Results of IMPLANTED (Italian Multicentre Observational Registry on Patients With Implantable) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 69	3.7	24
273	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace, 2018, 20, 895-896.	1.7	24
274	Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection. Internal and Emergency Medicine, 2021, 16, 1451-1456.	2.0	24
275	Transvenous Low Energy Internal Cardioversion for Atrial Fibrillation: A Review of Clinical Applications and Future Developments. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 99-107.	1.2	23
276	Automatic Management of Left Ventricular Stimulation: Hints for Technologic Improvement. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 346-353.	1.2	23
277	Phrenic stimulation management in CRT patients: are we there yet?. Current Opinion in Cardiology, 2011, 26, 12-16.	1.8	23
278	Longâ€Term RV Threshold Behavior by Automated Measurements: Safety is the Standpoint of Pacemaker Longevity!. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 89-95.	1.2	23
279	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1â€year outcomes in the EORPâ€AF General Pilot Registry. Journal of Cardiovascular Electrophysiology, 2018, 29, 566-572.	1.7	23
280	Impact of COVID-19 Pandemic on Remote Monitoring of Cardiac Implantable Electronic Devices in Italy: Results of a Survey Promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). Journal of Clinical Medicine, 2021, 10, 4086.	2.4	23
281	Predictors of Atrial Antitachycardia Pacing Efficacy in Patients Affected by Brady-Tachy Form of Sick Sinus Syndrome and Implanted with a DDDRP Device. Journal of Cardiovascular Electrophysiology, 2005, 16, 714-723.	1.7	22
282	Evolution of pacing for bradycardia: Autocapture. Country Review Ukraine, 2007, 9, I23-I32.	0.8	22
283	Atrial Threshold Variability: Implications for Automatic Atrial Stimulation Algorithms. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1445-1454.	1.2	22
284	Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 349-356.	0.5	22
285	Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace, 2011, 13, ii49-ii53.	1.7	22
286	Incidence and Predictors of Postoperative Atrial Fibrillation in Kidney Transplant Recipients. Transplantation, 2013, 96, 981-986.	1.0	22
287	New left ventricular active fixation lead: The experience of lead extraction. Indian Heart Journal, 2015, 67, S97-S99.	0.5	22
288	The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?. Europace, 2017, 19, 1826-1832.	1.7	22

#	Article	IF	Citations
289	Clinically oriented device programming in bradycardia patients: part 1 (sinus node disease). Proposals from AIAC (Italian Association of Arrhythmology and Cardiac Pacing). Journal of Cardiovascular Medicine, 2018, 19, 161-169.	1.5	22
290	Reactive atrialâ€based antitachycardia pacing therapy reduces atrial tachyarrhythmias. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 970-979.	1.2	22
291	Are atrial high rate episodes (AHREs) a precursor to atrial fibrillation?. Clinical Research in Cardiology, 2020, 109, 409-416.	3.3	22
292	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs, 2020, 80, 1065-1083.	10.9	22
293	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	3.4	22
294	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Medicine, 2021, 19, 256.	5.5	22
295	Usefulness of nicorandil in congestive heart failure. American Journal of Cardiology, 1990, 65, 343-348.	1.6	21
296	Nightmares and Sleep Disturbances with Simvastatin and Metoprolol. Annals of Pharmacotherapy, 2001, 35, 1292-1292.	1.9	21
297	Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry. European Heart Journal, 2009, 30, 2275-2283.	2.2	21
298	Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1201-1208.	1.2	21
299	Globalization of the Epidemiologic, Clinical, and Financial Burden of Atrial Fibrillation. Chest, 2012, 142, 1368-1370.	0.8	21
300	Effect of Cardiac Resynchronization Therapy on Left Atrial Size and Function as Expressed by Speckle Tracking 2-Dimensional Strain. American Journal of Cardiology, 2016, 118, 237-243.	1.6	21
301	Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database. Europace, 2016, 18, 1366-1373.	1.7	21
302	Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey. Health Economics (United Kingdom), 2017, 26, 124-144.	1.7	21
303	Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. European Journal of Internal Medicine, 2021, 85, 27-33.	2.2	21
304	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	3.2	21
305	Mechanisms of pain associated with internal defibrillation shocks: Results of a randomized study of shock waveform. Heart Rhythm, 2005, 2, 708-713.	0.7	20
306	Prediction of Cardiac Resynchronization Therapy Response. Circulation: Cardiovascular Imaging, 2010, 3, 86-93.	2.6	20

#	Article	IF	Citations
307	Psychological correlates, allostatic overload and clinical course in patients with implantable cardioverter defibrillator (ICD). International Journal of Cardiology, 2016, 220, 360-364.	1.7	20
308	Five year trends (2008â€“2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. Europace, 2018, 20, 643-653.	1.7	20
309	Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace, 2019, 21, 1764-1775.	1.7	20
310	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. Europace, 2019, 21, 636-644.	1.7	20
311	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	1.7	20
312	Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. European Journal of Preventive Cardiology, 2021, 28, 110-123.	1.8	20
313	Oral Loading with Propafenone: A Placebo-Controlled Study in Elderly and Nonelderly Patients with Recent Onset Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2465-2469.	1.2	19
314	Low Energy Internal Atrial Cardioversion in Atrial Fibrillation Lasting More Than a Year. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 243-246.	1.2	19
315	Electromechanical effects of cardiac resynchronization therapy during rest and stress in patients with heart failure. European Journal of Heart Failure, 2007, 9, 644-650.	7.1	19
316	The Drug And Pace Health cliNical Evaluation (DAPHNE) study: A randomized trial comparing sotalol versus Î²-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal, 2008, 156, 373.e1-373.e8.	2.7	19
317	Health economics and outcomes research: a new challenge and field of action for the European Heart Rhythm Association. Europace, 2010, 12, 601-603.	1.7	19
318	Cardiac resynchronization therapy: a cost or an investment?. Europace, 2011, 13, ii32-ii38.	1.7	19
319	Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England. Value in Health, 2021, 24, 930-938.	0.3	19
320	Mobile health technology in atrial fibrillation. Expert Review of Medical Devices, 2022, 19, 327-340.	2.8	19
321	Flecainide: evidence of non-linear kinetics. European Journal of Clinical Pharmacology, 1991, 41, 57-59.	1.9	18
322	Effect of left ventricular function on long-term left ventricular pacing and sensing threshold. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 21-24.	1.3	18
323	Left Ventricular versus Biventricular Pacing: A Randomized Comparative Study Evaluating Midâ€Term Electromechanical and Clinical Effects. Echocardiography, 2008, 25, 141-148.	0.9	18
324	Short-spaced dipole for managing phrenic nerve stimulation in patients with CRT: The â€œphrenic nerve mapping and stimulation EPâ€•catheter study. Heart Rhythm, 2013, 10, 39-45.	0.7	18

#	Article	IF	Citations
325	Implantation of cardioverter-defibrillator: Effects on shoulder function. International Journal of Cardiology, 2013, 168, 294-299.	1.7	18
326	Determinants of All-Cause Mortality in Different Age Groups in Patients With Severe Systolic Left Ventricular Dysfunction Receiving an Implantable Cardioverter Defibrillator (from the Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 T 1691-1696.	1.6	18
327	Cardiac resynchronization therapy and cardiac sympathetic function. European Journal of Clinical Investigation, 2015, 45, 792-799.	3.4	18
328	Cardiac resynchronization therapy: How did consensus guidelines from Europe and the United States evolve in the last 15â€¯years?. International Journal of Cardiology, 2018, 261, 119-129.	1.7	18
329	â€¯Real-worldâ€™ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	1.7	18
330	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	1.7	18
331	Antitachycardia pacing therapy to treat spontaneous atrial tachyarrhythmias: the 7250 dual defibrillator Italian Registry. European Heart Journal Supplements, 2001, 3, P25-P32.	0.1	17
332	Cardiac Resynchronization and Implantable Cardioverter Defibrillator Therapy: Preliminary Results from the InSync Implantable Cardioverter Defibrillator Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 148-151.	1.2	17
333	Effects of cardiac resynchronization therapy on coronary blood flow: Evaluation by transthoracic Doppler echocardiographyâ€†. European Journal of Heart Failure, 2008, 10, 514-520.	7.1	17
334	Is cardiac resynchronization therapy cost-effective?. Europace, 2009, 11, v93-v97.	1.7	17
335	Role of atrial fibrillation after transcatheter closure of patent foramen ovale in patients with or without cryptogenic stroke. International Journal of Cardiology, 2011, 146, 17-21.	1.7	17
336	Impact of Mitral Regurgitation on the Outcome of Patients Treated with CRTâ€Ð: Data from the InSync ICD Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 146-154.	1.2	17
337	Cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2014, 15, 147-154.	1.5	17
338	Detect Longâ€term Complications After ICD Replacement (DECODE): Rationale and Study Design of a Multicenter Italian Registry. Clinical Cardiology, 2015, 38, 577-584.	1.8	17
339	Non-valvular atrial fibrillation. Journal of Cardiovascular Medicine, 2015, 16, 491-496.	1.5	17
340	Automatic management of atrial and ventricular stimulation in a contemporary unselected population of pacemaker recipients: the ESSENTIAL Registry. Europace, 2016, 18, 1551-1560.	1.7	17
341	Clinically oriented device programming in bradycardia patients: part 2 (atrioventricular blocks and) Tj ETQq1 1 0.784314 rgBT /Overlo	1.5	17
342	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function. Internal and Emergency Medicine, 2018, 13, 1059-1067.	2.0	17

#	Article	IF	Citations
343	Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes. Nucleus, 2018, 9, 442-459.	2.2	17
344	Atrial Fibrillation and the Risk of Earlyâ€Onset Dementia: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2022, 11, .	3.7	17
345	High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: Favorable effects of D,L -sotalol. Heart and Lung: Journal of Acute and Critical Care, 2000, 29, 412-416.	1.6	16
346	Atrial Evoked Response Integral for Automatic Capture Verification in Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 248-252.	1.2	16
347	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs, 2007, 16, 605-623.	4.1	16
348	Cardiac resynchronization therapy in clinical practice: Need for electrical, mechanical, clinical and logistic synchronization. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 215-224.	1.3	16
349	Arrhythmia discrimination by physician and defibrillator: Importance of atrial channel. International Journal of Cardiology, 2012, 154, 134-140.	1.7	16
350	Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD. Indian Heart Journal, 2015, 67, 56-59.	0.5	16
351	The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies. Europace, 2017, 19, 1418-1426.	1.7	16
352	Implantable cardioverter-defibrillatorâ€“computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study. Heart Rhythm, 2018, 15, 211-217.	0.7	16
353	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 229-237.	4.0	16
354	Cardioverter-defibrillator oversensing due to double counting of ventricular tachycardia electrograms. International Journal of Cardiology, 1998, 66, 91-95.	1.7	15
355	Current clinical perspectives on implantable devices for atrial defibrillation. Current Opinion in Cardiology, 2002, 17, 82-89.	1.8	15
356	Implantable cardioverter defibrillators: from evidence of trials to clinical practice. Country Review Ukraine, 2007, 9, I66-I73.	0.8	15
357	Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental and Clinical Pharmacology, 2010, 24, 575-594.	1.9	15
358	How to truly value implantable cardioverter-defibrillators technology: Up-front cost or daily cost?. International Journal of Technology Assessment in Health Care, 2011, 27, 201-206.	0.5	15
359	Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm, 2013, 10, 214-218.	0.7	15
360	The OPTI-MIND study: a prospective, observational study of pacemaker patients according to pacing modality and primary indications. Europace, 2014, 16, 689-697.	1.7	15

#	Article	IF	Citations
361	Cost-effectiveness of implantable cardioverter-defibrillator in today's world. Indian Heart Journal, 2014, 66, S101-S104.	0.5	15
362	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. Clinical Research in Cardiology, 2019, 108, 1034-1041.	3.3	15
363	Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care. Journal of Cardiovascular Medicine, 2019, 20, 30-38.	1.5	15
364	Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. International Journal of Cardiology, 2021, 323, 83-89.	1.7	15
365	Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. Biomedicines, 2021, 9, 843.	3.2	15
366	Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 778-786.	4.0	15
367	COVID-19 pandemic: complex interactions with the arrhythmic profile and the clinical course of patients with cardiovascular disease. European Heart Journal, 2021, 42, 529-532.	2.2	15
368	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. Internal and Emergency Medicine, 2022, 17, 1001-1012.	2.0	15
369	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clinical Research in Cardiology, 2022, 111, 560-573.	3.3	15
370	Antitachycardia pacing therapies to terminate atrial tachyarrhythmias: the AT500 Italian Registry. European Heart Journal Supplements, 2001, 3, P16-P24.	0.1	14
371	Evaluation of a Dual Chamber Implantable Cardioverter Defibrillator for the Treatment of Atrial and Ventricular Arrhythmias. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 461-465.	1.2	14
372	Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. American Journal of Cardiology, 2004, 93, 371-373.	1.6	14
373	Acute and chronic haemodynamic effects of biventricular pacing and of switching to different pacing modalities in heart failure patients. International Journal of Cardiology, 2006, 110, 318-323.	1.7	14
374	Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device. Europace, 2006, 8, 465-473.	1.7	14
375	Left ventricular pacing by automatic capture verification. Europace, 2007, 9, 1177-1181.	1.7	14
376	Effect of Cardiac Resynchronization Therapy on Subendo- and Subepicardial Left Ventricular Twist Mechanics and Relation to Favorable Outcome. American Journal of Cardiology, 2010, 106, 682-687.	1.6	14
377	Ventricular rate monitoring as a tool to predict and prevent atrial fibrillation-related inappropriate shocks in heart failure patients treated with cardiac resynchronisation therapy defibrillators. Heart, 2014, 100, 848-854.	2.9	14
378	Holter ECG for pacemaker/defibrillator carriers: what is its role in the era of remote monitoring?. Heart, 2015, 101, 1272-1278.	2.9	14

#	Article	IF	Citations
379	Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise. Heart Lung and Circulation, 2016, 25, 476-483.	0.4	14
380	Arrhythmias Originating in the Atria. Cardiac Electrophysiology Clinics, 2017, 9, 383-409.	1.7	14
381	Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress. Cellular Physiology and Biochemistry, 2017, 42, 169-184.	1.6	14
382	Comparison of cryoballoon and radiofrequency ablation techniques for atrial fibrillation: a meta-analysis. Journal of Cardiovascular Medicine, 2018, 19, 725-738.	1.5	14
383	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. International Journal of Cardiology, 2019, 296, 65-70.	1.7	14
384	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRXâ„¢ antibacterial envelope. Europace, 2021, 23, iv33-iv44.	1.7	14
385	Incidence and Predictors of Infections and All-Cause Death in Patients with Cardiac Implantable Electronic Devices: The Italian Nationwide RI-AIAC Registry. Journal of Personalized Medicine, 2022, 12, 91.	2.5	14
386	Transvenous Cardioverter-Defibrillator Implantation in a Patient with Tricuspid Mechanical Prosthesis. Journal of Cardiovascular Electrophysiology, 2007, 18, 329-331.	1.7	13
387	Atrial Fibrillation Therapy in Patients with a CRT Defibrillator with Wireless Telemetry. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 13-23.	1.2	13
388	Balancing the Risk of Hemorrhage vs Thromboembolism in Patients With Atrial Fibrillation. Chest, 2010, 138, 1032-1033.	0.8	13
389	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. Journal of Internal Medicine, 2016, 279, 467-476.	6.0	13
390	The ventricular ectopic QRS interval (VEQSI): Diagnosis of arrhythmogenic right ventricular cardiomyopathy in patients with incomplete disease expression. Heart Rhythm, 2016, 13, 1504-1512.	0.7	13
391	Role of cardiovascular imaging in cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2018, 19, 211-222.	1.5	13
392	Favorable Trend of Implantable Cardioverterâ€Defibrillator Service Life in a Large Singleâ€Nation Population: Insights From 10â€Year Analysis of the Italian Implantable Cardioverterâ€Defibrillator Registry. Journal of the American Heart Association, 2019, 8, e012759.	3.7	13
393	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 1561-1567.	1.6	13
394	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. Neuropsychobiology, 2019, 77, 67-72.	1.9	13
395	Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study. European Journal of Internal Medicine, 2019, 62, 9-16.	2.2	13
396	Effect of high-pass filtering on ECG signal on the analysis of patients prone to atrial fibrillation. Annali Dell'Istituto Superiore Di Sanita, 2009, 45, 427-31.	0.4	13

#	Article	IF	Citations
397	Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis. Current Pharmaceutical Design, 2017, 23, 944-951.	1.9	13
398	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. European Journal of Internal Medicine, 2022, 103, 84-94.	2.2	13
399	Transvenous internal cardioversion for atrial fibrillation: a randomized study on defibrillation threshold and tolerability of asymmetrical compared with symmetrical shocks. International Journal of Cardiology, 1999, 71, 63-69.	1.7	12
400	Effects of consistent atrial pacing and atrial rate stabilization - two pacing algorithms to suppress recurrent paroxysmal atrial fibrillation in brady-tachy syndrome. European Heart Journal Supplements, 2001, 3, P7-P15.	0.1	12
401	Quantification of Fatty Tissue Mass by Magnetic Resonance Imaging in Arrhythmogenic Right Ventricular Dysplasia. Journal of Cardiovascular Electrophysiology, 2005, 16, 256-261.	1.7	12
402	Biventricular vs. left univentricular pacing in heart failure: rationale, design, and endpoints of the B-LEFT HF study. Europace, 2006, 8, 76-80.	1.7	12
403	Remote monitoring of cardiac implantable electrical devices in Europe: quo vadis?. Europace, 2015, 17, 674-676.	1.7	12
404	Effect of fixed-rate vs. rate-RESPONSIve pacing on exercise capacity in patients with permanent, refractory atrial fibrillation and left ventricular dysfunction treated with atrioventricular junction aBLation and bivEntricular pacing (RESPONSIBLE): a prospective, multicentre, randomized, single-blind study. Europace, 2017, 19, euw035.	1.7	12
405	Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial. Heart Rhythm, 2017, 14, 1476-1484.	0.7	12
406	Cardiac Resynchronization Therapy. Heart Failure Clinics, 2017, 13, 117-137.	2.1	12
407	Screening for atrial fibrillation: Need for an integrated, structured approach. European Journal of Internal Medicine, 2019, 67, 33-35.	2.2	12
408	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. Orphanet Journal of Rare Diseases, 2019, 14, 263.	2.7	12
409	Clinical and organizational management of cardiac implantable electronic device replacements. Journal of Cardiovascular Medicine, 2019, 20, 531-541.	1.5	12
410	Cardiac Electronic Devices: Future Directions and Challenges . Medical Devices: Evidence and Research, 2020, Volume 13, 325-338.	0.8	12
411	Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation. Current Pharmaceutical Design, 2021, 27, 3901-3912.	1.9	12
412	Meta-analysis of Clinical Outcomes of Electrical Cardioversion and Catheter Ablation in Patients with Atrial Fibrillation and Chronic Kidney Disease. Current Pharmaceutical Design, 2018, 24, 2794-2801.	1.9	12
413	Atrial fibrillation in patients with cardiac implantable electronic devices: new perspectives with important clinical implications. Kardiologia Polska, 2019, 77, 1119-1120.	0.6	12
414	Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey. Heart Rhythm, 2022, 19, 206-216.	0.7	12

#	Article	IF	Citations
415	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. Europace, 2022, 24, 721-728.	1.7	12
416	Implantable cardioverter defibrillators and devices for cardiac resynchronization therapy: what perspective for patientsâ€™ apps combined with remote monitoring?. Expert Review of Medical Devices, 2022, 19, 155-160.	2.8	12
417	Atrial cardiomyopathy: a derangement in atrial volumes, geometry, function, and pathology with important clinical implications. Journal of Cardiovascular Medicine, 2022, 23, 359-362.	1.5	12
418	Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response. Archives of Gerontology and Geriatrics, 1998, 27, 127-139.	3.0	11
419	Predictors of Atrial Defibrillation Threshold in Internal Cardioversion. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1898-1901.	1.2	11
420	Long-term reduction of atrial tachyarrhythmia recurrences in patients paced for bradycardia-tachycardia syndrome. Heart Rhythm, 2005, 2, 1047-1057.	0.7	11
421	Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. American Heart Journal, 2006, 152, 527.e1-527.e11.	2.7	11
422	How, Why, and When May Atrial Defibrillation Find a Specific Role in Implantable Devices? A Clinical Viewpoint. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 422-433.	1.2	11
423	Troponin I Rise After Pacemaker Implantation at the Time of â€œUniversal Definition of Myocardial Infarctionâ€• American Journal of Cardiology, 2009, 103, 1061-1065.	1.6	11
424	Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling. Current Drug Targets, 2011, 12, 263-286.	2.1	11
425	Predicting the Quality of Anticoagulation During Warfarin Therapy. Chest, 2013, 144, 1437-1438.	0.8	11
426	Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm, 2015, 12, 1192-1200.	0.7	11
427	Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs. European Journal of Clinical Pharmacology, 2015, 71, 1001-1009.	1.9	11
428	Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. Nuclear Medicine and Biology, 2015, 42, 858-863.	0.6	11
429	The struggle against infections of cardiac implantable electrical devices: the burden of costs requires new personalized solutions. Europace, 2018, 20, 1877-1879.	1.7	11
430	Is ventricular sensing always right, when it is left?. Clinical Cardiology, 2018, 41, 1238-1245.	1.8	11
431	Neuro-arrhythmology. Journal of Cardiovascular Medicine, 2019, 20, 731-744.	1.5	11
432	Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs. American Journal of Cardiovascular Drugs, 2020, 20, 125-137.	2.2	11

#	Article	IF	Citations
433	Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes. Internal and Emergency Medicine, 2021, 16, 1771-1777.	2.0	11
434	Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2021, 70, 102071.	2.6	11
435	Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective. Europace, 2022, 24, 1541-1547.	1.7	11
436	Efficacy of internal cardioversion for chronic atrial fibrillation in patients with and without left ventricular dysfunction. International Journal of Cardiology, 2004, 95, 43-47.	1.7	10
437	Implantable Dual-Chamber Defibrillator for the Selective Treatment of Spontaneous Atrial and Ventricular Arrhythmias: Arrhythmia Incidence and Device Performance. Journal of Interventional Cardiac Electrophysiology, 2005, 12, 149-156.	1.3	10
438	Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome. American Heart Journal, 2007, 154, 193-200.	2.7	10
439	Temporal Variability of Atrial Fibrillation in Pacemaker Recipients for Bradycardia: Implications for Crossover Designed Trials, Study Sample Size, and Identification of Responder Patients by Means of Arrhythmia Burden. Journal of Cardiovascular Electrophysiology, 2007, 18, 250-257.	1.7	10
440	Painless Shock Therapy: More Than Just an Attempt to Square the Circle?. Journal of Cardiovascular Electrophysiology, 2007, 18, 1101-1103.	1.7	10
441	Atrial fibrillation: Adverse effects of â€œpill-in-the-pocketâ€•treatment and propafenoneâ€“carvedilol interaction. International Journal of Cardiology, 2010, 140, 242-243.	1.7	10
442	On the resolution of ECG acquisition systems for the reliable analysis of the P-wave. Physiological Measurement, 2012, 33, N11-N17.	2.1	10
443	Acute changes in electromechanical parameters during different pacing configurations using a quadripolar left ventricular lead. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 61-69.	1.3	10
444	Clinical management of electromagnetic interferences in patients with pacemakers and implantable cardioverter-defibrillators. Journal of Cardiovascular Medicine, 2015, 16, 704.	1.5	10
445	Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications. European Heart Journal, 2017, 38, 2129-2131.	2.2	10
446	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	2.5	10
447	Efficacy of cardiac resynchronization therapy in patients with isolated ventricular noncompaction with dilated cardiomyopathy: a systematic review of the literature. Journal of Cardiovascular Medicine, 2018, 19, 324-328.	1.5	10
448	Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). American Journal of Cardiology, 2019, 123, 592-597.	1.6	10
449	Managing atrial fibrillation: the need for an individualized approach even in the emergency department. Internal and Emergency Medicine, 2020, 15, 9-12.	2.0	10
450	Effects of Anti-vitamin k oral anticoagulants on bone and cardiovascular health. European Journal of Internal Medicine, 2020, 79, 1-11.	2.2	10

#	Article	IF	Citations
451	Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients. European Journal of Heart Failure, 2020, 22, 554-556.	7.1	10
452	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace, 2021, 23, 1873-1891.	1.7	10
453	Impact of renal impairment on atrial fibrillation: ESCâ€EHRA EORPâ€AF Longâ€Term General Registry. European Journal of Clinical Investigation, 2022, 52, e13745.	3.4	10
454	Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices: Dynamic Changes in Episodes and Predictors of Incident Atrial Fibrillation. Biology, 2022, 11, 443.	2.8	10
455	AIMâ€AF: A Physician Survey in the United States and Europe. Journal of the American Heart Association, 2022, 11, e023838.	3.7	10
456	Drugs, gery, Cardioverter Defibrillator: A Decision Based on the Clinical Problem. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 519-527.	1.2	9
457	Clinical experience with downsized lower energy output implantable cardioverter defibrillators. International Journal of Cardiology, 1998, 66, 261-266.	1.7	9
458	A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. European Journal of Clinical Pharmacology, 2002, 58, 165-169.	1.9	9
459	Atrial Signal Analysis and Defibrillation Threshold Assessment in Chronic Persistent and Reinduced Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2002, 13, 449-454.	1.7	9
460	Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. International Journal of Cardiology, 2004, 95, 245-250.	1.7	9
461	Duration of P-Wave Is Associated with Atrial Fibrillation Hospitalizations in Patients with Atrial Fibrillation and Paced for Bradycardia. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 961-969.	1.2	9
462	Uneventful Right Ventricular Perforation With Displacement of a Pacing Lead Into the Left Thorax. Journal of Cardiothoracic and Vascular Anesthesia, 2008, 22, 423-425.	1.3	9
463	Trialâ€generated profiles for implantation of electrical devices in outpatients with heart failure: realâ€world prevalence and 1â€year outcome. Journal of Evaluation in Clinical Practice, 2010, 16, 82-91.	1.8	9
464	Excimer laser lead extraction by femoral approach. Europace, 2011, 13, 757-759.	1.7	9
465	Tailored treatment strategies: a new approach for modern management of atrial fibrillation. Journal of Internal Medicine, 2016, 279, 457-466.	6.0	9
466	Atrial Fibrillation and Aging. Chest, 2016, 149, 301-302.	0.8	9
467	Patient outcome after implant of a cardioverter defibrillator in the â€˜real worldâ€™: the key role of coâ€morbidities. European Journal of Heart Failure, 2017, 19, 387-390.	7.1	9
468	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. International Journal of Cardiology, 2017, 248, 166-172.	1.7	9

#	Article	IF	Citations
469	Extending survival by reducing sudden death with implantable cardioverterâ€defibrillators: a challenging clinical issue in nonâ€ischaemic and ischaemic cardiomyopathies. European Journal of Heart Failure, 2018, 20, 420-426.	7.1	9
470	Cardiac resynchronization therapy in the real world: need to upgrade outcome research. European Journal of Heart Failure, 2018, 20, 1469-1471.	7.1	9
471	Long-term progression of rhythm and conduction disturbances in pacemaker recipients: findings from the Pacemaker Expert Programming study. Journal of Cardiovascular Medicine, 2018, 19, 357-365.	1.5	9
472	Radiotherapy-induced malfunctions of cardiac implantable electronic devices in cancer patients. Internal and Emergency Medicine, 2020, 15, 967-973.	2.0	9
473	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. European Journal of Internal Medicine, 2020, 80, 35-44.	2.2	9
474	Kidney dysfunction and short term all-cause mortality after transcatheter aortic valve implantation. European Journal of Internal Medicine, 2020, 81, 32-37.	2.2	9
475	Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. Thrombosis and Haemostasis, 2022, 122, 171-175.	3.4	9
476	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. Europace, 2022, 24, 202-210.	1.7	9
477	Red Cell Distribution Width and Patient Outcome in Cardiovascular Disease: A â€˜â€™Real-Worldâ€™â€™ Analysis. Journal of Cardiovascular Development and Disease, 2021, 8, 120.	1.6	9
478	The Impact of COVID-19 Pandemic and Lockdown Restrictions on Cardiac Implantable Device Recipients with Remote Monitoring. Journal of Clinical Medicine, 2021, 10, 5626.	2.4	9
479	Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors. Cardiology Journal, 2022, 29, 163-165.	1.2	9
480	Repolarization Changes in a Doubleâ€Blind Crossover Study of Dofetilide Versus Sotalol in the Treatment of Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1935-1938.	1.2	8
481	Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverterâ€“defibrillator implant. International Journal of Cardiology, 2002, 83, 171-173.	1.7	8
482	Fluttering waves in electrocardiograms recorded in neonatal intensive care unit. International Journal of Cardiology, 2003, 92, 299-301.	1.7	8
483	Evaluation of the Atrial Evoked Response for Capture Detection with High-Polarization Leads. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S57-S62.	1.2	8
484	Pacing with capture verification in candidates for resynchronisation therapy: A feasibility study. Europace, 2005, 7, 255-265.	1.7	8
485	Relevance of cardioverter defibrillators for the prevention of sudden cardiac death on the timing of heart transplantation. Clinical Transplantation, 2006, 20, 684-688.	1.6	8
486	Primary Prevention of Sudden Cardiac Death: Can We Afford the Cost of Cardioverter-Defibrillators? Data from the Search-MI Registry-Italian Sub-study. PACE - Pacing and Clinical Electrophysiology, 2006, 29, S29-S34.	1.2	8

#	Article	IF	Citations
487	Remote Monitoring of Patients with an Implanted Device and Patientsâ€™ Outcomes: The Potential for â€œWinâ€Winâ€•Dynamics. Journal of Cardiovascular Electrophysiology, 2009, 20, 1252-1254.	1.7	8
488	Changes in exercise capacity induced by heart transplantation: prognostic and therapeutic implications. Scandinavian Journal of Medicine and Science in Sports, 2011, 21, 519-525.	2.9	8
489	Assessing the outcomes of implantable cardioverter defibrillator treatment in a real world setting: results from hospital record data. BMC Health Services Research, 2013, 13, 100.	2.2	8
490	The Epidemiologic Threat of Atrial Fibrillation. Chest, 2015, 147, 9-10.	0.8	8
491	Left Ventricular Reverse Remodeling Elicited by a Quadripolar Lead: Results from the Multicenter Per4mer Study. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 250-260.	1.2	8
492	Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation. International Journal of Cardiology, 2017, 230, 275-280.	1.7	8
493	Edoxaban in Atrial Fibrillation and Venous Thromboembolismâ€”Ten Key Questions and Answers: A Practical Guide. Advances in Therapy, 2017, 34, 620-637.	2.9	8
494	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. Journal of Nuclear Cardiology, 2019, 26, 123-132.	2.1	8
495	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. Cells, 2020, 9, 1532.	4.1	8
496	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f81-f83.	3.0	8
497	How did COVID-19 affect medical and cardiology journals? A pandemic in literature. Journal of Cardiovascular Medicine, 2021, 22, 840-847.	1.5	8
498	Î²-Blocking Properties of Propafenone in Extensive Oxidisers: A Study on Heart Rate Behaviour during Holter Monitoring. Drug Investigation, 1993, 6, 25-32.	0.6	7
499	Late Improvement in Ventricular Performance Following Internal Cardioversion for Persistent Atrial Fibrillation:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1218-1226.	1.2	7
500	Comparison of Induced and Spontaneous Atrial Tachyarrhythmias in Patients with a History of Spontaneous Atrial Tachyarrhythmias. Journal of Cardiovascular Electrophysiology, 2005, 16, 818-822.	1.7	7
501	Automatic Verification of Ventricular Stimulation: Fusion Management Algorithm. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 64-69.	1.2	7
502	Interventricular Delay Optimization: A Comparison among Three Different Echocardiographic Methods. Echocardiography, 2010, 27, 38-43.	0.9	7
503	Longâ€Term Followâ€Up of Patients with Syncope Evaluated by Headâ€Up Tilt Test. Annals of Noninvasive Electrocardiology, 2010, 15, 101-106.	1.1	7
504	Clinical Management of Atrial Fibrillation. Chest, 2011, 140, 843-845.	0.8	7

#	Article	IF	Citations
505	QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. British Journal of Clinical Pharmacology, 2011, 72, 839-841.	2.4	7
506	Short-term onset of fatal pulmonary toxicity in a patient treated with intravenous amiodarone for post-operative atrial fibrillation. International Journal of Cardiology, 2012, 159, e1-e4.	1.7	7
507	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	2.7	7
508	Stroke/Thromboembolism and Intracranial Hemorrhage in a Real-world Atrial Fibrillation Population. Chest, 2014, 146, 1073-1080.	0.8	7
509	Clinically guided pacemaker choice and setting: pacemaker expert programming study. Europace, 2016, 19, euw256.	1.7	7
510	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. Europace, 2016, 18, 1507-1513.	1.7	7
511	Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care. International Journal of Cardiology, 2018, 261, 73-77.	1.7	7
512	New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes. Echocardiography, 2019, 36, 38-46.	0.9	7
513	Optimal Use of Echocardiography in Management of Thrombosis After Anterior Myocardial Infarction. Echocardiography, 2020, 37, 1287-1295.	0.9	7
514	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. European Journal of Internal Medicine, 2020, 74, 55-60.	2.2	7
515	Echocardiographic Left Ventricular Mass Assessment: Correlation between 2D-Derived Linear Dimensions and 3-Dimensional Automated, Machine Learning-Based Methods in Unselected Patients. Journal of Clinical Medicine, 2021, 10, 1279.	2.4	7
516	The challenge to improve knowledge on the interplay between subclinical atrial fibrillation, atrial cardiomyopathy, and atrial remodeling. Journal of Cardiovascular Electrophysiology, 2021, 32, 1364-1366.	1.7	7
517	Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. Journal of Clinical Medicine, 2021, 10, 2879.	2.4	7
518	Costâ€minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing <scp>ICD</scp> explant procedures: Clinical and economic implications. Clinical Cardiology, 2021, 44, 1497-1505.	1.8	7
519	Reshaping of Italian Echocardiographic Laboratories Activities during the Second Wave of COVID-19 Pandemic and Expectations for the Post-Pandemic Era. Journal of Clinical Medicine, 2021, 10, 3466.	2.4	7
520	COVID-19 pandemic: usefulness of telemedicine in management of arrhythmias in elderly people. Journal of Geriatric Cardiology, 2020, 17, 593-596.	0.2	7
521	Intravenous administration of propafenone. Journal of the American College of Cardiology, 1992, 19, 1368.	2.8	6
522	Clinical reliability of single-lead VDD pacing from evaluation of p-wave sensing under dynamic conditions. American Journal of Cardiology, 1998, 82, 676-679.	1.6	6

#	Article	IF	Citations
523	Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal cardioversion in patients with chronic persistent atrial fibrillation. Cardiovascular Drugs and Therapy, 1999, 13, 507-511.	2.6	6
524	Neurocardiogenic syncope in selected pediatric patients--natural history during long-term follow-up and effect of prophylactic pharmacological therapy. Cardiovascular Drugs and Therapy, 2001, 15, 161-167.	2.6	6
525	New Options for Pharmacological Conversion of Atrial Fibrillation. , 2001, 5, 195-200.		6
526	A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker. International Journal of Cardiology, 2005, 104, 73-76.	1.7	6
527	Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death: A Cost or an Investment?. Value in Health, 2007, 10, 1-2.	0.3	6
528	Plateau Waveform Shape Allows a Much Higher Patient Shock Energy Tolerance in AF Patients. Journal of Cardiovascular Electrophysiology, 2007, 18, 728-734.	1.7	6
529	Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators. Europace, 2008, 10, 918-925.	1.7	6
530	Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia. Current Medicinal Chemistry, 2008, 15, 2472-2517.	2.4	6
531	Incompatibility between intravenous amiodarone and heparin in an infant. International Journal of Cardiology, 2010, 145, e70-e73.	1.7	6
532	Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial. Trials, 2011, 12, 44.	1.6	6
533	Effects of cardiac resynchronization therapy on myocardial contractile reserve during exercise. European Journal of Heart Failure, 2011, 13, 406-411.	7.1	6
534	Health economics and the European Heart Rhythm Association. Europace, 2011, 13, ii1-ii2.	1.7	6
535	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. European Journal of Clinical Pharmacology, 2013, 69, 715-720.	1.9	6
536	Cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2014, 15, 269-272.	1.5	6
537	Ventricular antitachycardia pacing therapy in patients with heart failure implanted with a cardiac resynchronization therapy defibrillator device: Efficacy, safety, and impact on mortality. Heart Rhythm, 2016, 13, 472-480.	0.7	6
538	Impact of pacemaker longevity on expected device replacement rates: Results from computer simulations based on a multicenter registry (ESSENTIAL). Clinical Cardiology, 2018, 41, 1185-1191.	1.8	6
539	Remodeling classification system considering left ventricular volume in patients with aortic valve stenosis: Association with adverse cardiovascular outcomes. Echocardiography, 2019, 36, 639-650.	0.9	6
540	Temporary transvenous cardiac pacing. Journal of Cardiovascular Medicine, 2020, 21, 420-427.	1.5	6

#	Article	IF	Citations
541	Complicated myocardial infarction in a 99-year-old lady in the era of COVID-19 pandemic: from the need to rule out coronavirus infection to emergency percutaneous coronary angioplasty. Internal and Emergency Medicine, 2020, 15, 835-839.	2.0	6
542	Cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy: single center implant data extracted from the Swedish pacemaker and ICD registry. Scandinavian Cardiovascular Journal, 2020, 54, 239-247.	1.2	6
543	Anticoagulation to prevent ischaemic stroke in patients with atrial fibrillation: a complex scenario including underdiagnosis, undertreatment, or underdosing of oral anticoagulants. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 95-97.	4.0	6
544	Organization and procedures in contemporary catheter ablation centres: data from the 2018 Italian Catheter Ablation Registry. Journal of Cardiovascular Medicine, 2021, 22, 631-636.	1.5	6
545	Clinical Value of Complex Echocardiographic Left Ventricular Hypertrophy Classification Based on Concentricity, Mass, and Volume Quantification. Frontiers in Cardiovascular Medicine, 2021, 8, 667984.	2.4	6
546	Impact of body mass index on the outcome of elderly patients treated with transcatheter aortic valve implantation. Internal and Emergency Medicine, 2022, 17, 369-376.	2.0	6
547	Transvenous internal cardioversion for atrial fibrillation: A randomized comparison between catheters with different coil length. American Heart Journal, 2002, 144, 851-857.	2.7	6
548	Impact of COVID-19 in emergency medicine literature: a bibliometric analysis. Internal and Emergency Medicine, 2022, 17, 1229-1233.	2.0	6
549	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESCâ€EHRA EURObservational research programme in atrial fibrillation general longâ€term registry. European Journal of Clinical Investigation, 2022, 52, e13773.	3.4	6
550	Arrhythmias in COVID-19/SARS-CoV-2 Pneumonia Infection: Prevalence and Implication for Outcomes. Journal of Clinical Medicine, 2022, 11, 1463.	2.4	6
551	The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. International Journal of Cardiology, 2022, 356, 12-18.	1.7	6
552	Abnormal Cardiac Innervation in Patients with Idiopathic Ventricular Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 357-360.	1.2	5
553	Optimization of Pacing Algorithms to Prevent and Treat Supraventricular Tachyarrhythmias. PACE - Pacing and Clinical Electrophysiology, 2006, 29, S61-S72.	1.2	5
554	Resolution of atrial thrombosis with heparin in a newborn with atrial flutter. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 1211-1214.	1.5	5
555	Radionuclide Angiographic Determination of Regional Left Ventricular Systolic Function During Rest and Exercise in Patients With Nonischemic Cardiomyopathy Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2010, 106, 389-394.	1.6	5
556	QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study. BMC Cardiovascular Disorders, 2012, 12, 27.	1.7	5
557	Massive Pulmonary Embolism with Acute Coronary Syndrome-like Electrocardiogram Mimicking Acute Left Main Coronary ArteryÂObstruction. Journal of Emergency Medicine, 2012, 43, e255-e258.	0.7	5
558	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. Europace, 2015, 17, 1319-1322.	1.7	5

#	Article	IF	Citations
559	BLOCK HF. Journal of Cardiovascular Medicine, 2016, 17, 306-308.	1.5	5
560	The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. Europace, 2017, 19, 1767-1775.	1.7	5
561	Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1483-1488.	2.0	5
562	Cardiac involvement in systemic sclerosis. Journal of Cardiovascular Medicine, 2018, 19, 393-395.	1.5	5
563	Infective endocarditis in patients with cardiac implantable electronic devices: Impact of comorbidities on outcome. European Journal of Internal Medicine, 2019, 66, e9-e10.	2.2	5
564	Occurrence of atrial fibrillation in pacemaker patients and its association with sleep apnea and heart rate variability. European Journal of Internal Medicine, 2019, 68, 13-17.	2.2	5
565	Imaging functional stress test for stable chest pain symptoms in patients at low pretest probability of coronary artery disease: Current practice and longâ€term outcome. Echocardiography, 2019, 36, 1095-1102.	0.9	5
566	The 12-lead ECG: a continuous reference for the cardiologist. Journal of Cardiovascular Medicine, 2019, 20, 459-463.	1.5	5
567	Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores. European Journal of Preventive Cardiology, 2020, 27, 726-728.	1.8	5
568	Shoulder Function After Cardioverter-Defibrillator Implantation: 5-YearÂFollow-up. Annals of Thoracic Surgery, 2020, 110, 608-614.	1.3	5
569	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy, 2020, 18, 587-600.	1.5	5
570	Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythmia and Electrophysiology Review, 2012, 1, 54.	2.4	5
571	¹¹C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. Current Radiopharmaceuticals, 2014, 7, 79-83.	0.8	5
572	Digital literacy as a potential barrier to implementation of cardiology tele-visits after COVID-19 pandemic: the INFO-COVID survey. Journal of Geriatric Cardiology, 2021, 18, 739-747.	0.2	5
573	Cardioversion of recent-onset atrial fibrillation: current evidence, practical considerations, and controversies in a complex clinical scenario. Kardiologia Polska, 2020, 78, 1088-1098.	0.6	5
574	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. Journal of Clinical Medicine, 2022, 11, 891.	2.4	5
575	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. European Journal of Internal Medicine, 2022, 99, 45-56.	2.2	5
576	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. European Journal of Internal Medicine, 2022, 103, 41-49.	2.2	5

#	Article	IF	Citations
577	The search for a gold standard to clinically diagnose and monitor atrial cardiomyopathy. European Journal of Internal Medicine, 2022, 101, 34-36.	2.2	5
578	Qrs interval time-related changes and prognosis in heart failure. American Journal of Cardiology, 2003, 91, 514.	1.6	4
579	Evaluation of Fusion Beat Detection with a New Ventricular Automatic Capture Algorithm in ICDs. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S263-S266.	1.2	4
580	Heart failure after myocardial revascularization: Risk markers. International Journal of Cardiology, 2005, 105, 11-14.	1.7	4
581	A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. Europace, 2008, 11, 1-3.	1.7	4
582	Changes in global longitudinal strain during rest and exercise in patients treated with cardiac resynchronization therapy. Clinical Physiology and Functional Imaging, 2012, 32, 310-316.	1.2	4
583	Influence of time between last myocardial infarction and prophylactic implantable defibrillator implant on device detections and therapies. â€œRoutine Practiceâ€•data from the SEARCH MI registry. BMC Cardiovascular Disorders, 2012, 12, 72.	1.7	4
584	Letter by Gasparini and Boriani Regarding Article, â€œCardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)â€• Circulation: Heart Failure, 2013, 6, e22.	3.9	4
585	Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 673-693.	1.7	4
586	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. Arrhythmia and Electrophysiology Review, 2016, 5, 210.	2.4	4
587	Predictors of nonsimultaneous interventricular delay at cardiac resynchronization therapy optimization. Journal of Cardiovascular Medicine, 2016, 17, 299-305.	1.5	4
588	Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database. Europace, 2016, 18, 1391-1398.	1.7	4
589	A closer look into the complexity of our practice: Outcome research for transvenous temporary cardiac pacing. International Journal of Cardiology, 2018, 271, 117-118.	1.7	4
590	Lead choice in cardiac implantable electronic devices: an Italian survey promoted by AIAC (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	2.8	4
591	Continuous monitoring of <scp>sleepâ€disordered</scp> breathing with pacemakers: Indexes for risk stratification of atrial fibrillation and risk of stroke. Clinical Cardiology, 2020, 43, 1609-1615.	1.8	4
592	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. Expert Review of Medical Devices, 2020, 17, 297-308.	2.8	4
593	Biomarkers in atrial fibrillation: a constant search for simplicity, practicality, and cost-effectiveness. Kardiologia Polska, 2021, 79, 243-245.	0.6	4
594	Red blood cell distribution width in patients undergoing transcatheter aortic valve implantation: Implications for outcomes. International Journal of Clinical Practice, 2021, 75, e14153.	1.7	4

#	Article	IF	Citations
595	Burden of disease and costs of infections associated with cardiac implantable electronic devices. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 7-16.	1.4	4
596	12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility. Journal of Cardiovascular Echography, 2018, 28, 32.	0.4	4
597	European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice. Journal of Cardiovascular Echography, 2018, 28, 26.	0.4	4
598	Clinical management of electrical storm: a current overview. Journal of Cardiovascular Medicine, 2021, 22, 669-679.	1.5	4
599	Atrial high rate episodes as a marker of atrial cardiomyopathy: In the quest of the Holy Grail. Author's reply. European Journal of Internal Medicine, 2022, 98, 115-116.	2.2	4
600	Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients. Journal of Cardiovascular Pharmacology, 2022, 79, 472-478.	1.9	4
601	Dronedarone for the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long odyssey?. European Journal of Heart Failure, 2022, 24, 1102-1105.	7.1	4
602	DDD and single-lead VDD pacing: Evaluation of atrial signal dynamic changes. Clinical Cardiology, 2000, 23, 678-680.	1.8	3
603	Atrial Fibrillation in Patients with a Dual Defibrillator: Characteristics of Spontaneous and Induced Episodes and Effect of Ventricular Tachyarrhythmia Induction. Journal of Cardiovascular Electrophysiology, 2005, 16, 974-980.	1.7	3
604	Letter Regarding Article by Bokhari et al, â€œLong-Term Comparison of the Implantable Cardioverter Defibrillator Versus Amiodarone: Eleven-Year Follow-Up of a Subset of Patients in the Canadian Implantable Defibrillator Study (CIDS)â€• Circulation, 2005, 111, e26; author reply e26.	1.6	3
605	AB7-2. Heart Rhythm, 2006, 3, S13.	0.7	3
606	Ventricular dyssynchrony at echo: Detection by two-dimensional tracking and tissue doppler imaging in candidates to biventricular pacing. , 2008, , .		3
607	Decrease in Patient Radiation Exposure by a Tantalum Filter during Electrophysiological Procedures. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S109-S112.	1.2	3
608	Prophylactic cardioverter defibrillator utilization in the ?real world?: A conundrum. International Journal of Cardiology, 2012, 156, 123-124.	1.7	3
609	The â€œrope and stickâ€•and the â€œsafety snareâ€• Two new techniques for tricky lead extractions. International Journal of Cardiology, 2012, 157, 449-451.	1.7	3
610	How to RESPOND to the quest to increase the effectiveness of cardiac resynchronization therapy?. European Heart Journal, 2017, 38, ehw595.	2.2	3
611	Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. Current Medical Research and Opinion, 2017, 33, 1175-1177.	1.9	3
612	The effects of gender on electrical therapies for the heart: procedural considerations, results and complications. Europace, 2017, 19, 1911-1921.	1.7	3

#	Article	IF	Citations
613	Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients. Clinical Cardiology, 2017, 40, 377-382.	1.8	3
614	Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol. Pulmonary Pharmacology and Therapeutics, 2018, 49, 147-151.	2.6	3
615	Management of cardiopulmonary disease in patients with systemic sclerosis. Journal of Cardiovascular Medicine, 2018, 19, 513-515.	1.5	3
616	Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. New England Journal of Medicine, 2019, 381, 385-388.	27.0	3
617	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. European Journal of Heart Failure, 2019, 21, 690-693.	7.1	3
618	Cardiomyopathy associated with longâ€term right ventricular pacing: an intriguing clinical issue. European Journal of Heart Failure, 2019, 21, 652-654.	7.1	3
619	Female sex and stroke in atrial fibrillation: an intriguing relationship. Internal and Emergency Medicine, 2020, 15, 175-179.	2.0	3
620	Temporal patterns of premature atrial complexes predict atrial fibrillation occurrence in bradycardia patients continuously monitored through pacemaker diagnostics. Internal and Emergency Medicine, 2020, 15, 599-606.	2.0	3
621	Inhibition of lysyl oxidase stimulates TGF-Î² signaling and metalloproteinases-2 and -9 expression and contributes to the disruption of ascending aorta in rats: protection by propylthiouracil. Heart and Vessels, 2021, 36, 738-747.	1.2	3
622	Updating a simple clinical score predicting incident atrial fibrillation: The CHEST score or more (mCHEST)?. European Journal of Internal Medicine, 2021, 90, 27-29.	2.2	3
623	Clinical implications of assessing frailty in elderly patients treated with permanent cardiac pacing. Journal of Cardiovascular Medicine, 2022, 23, 87-90.	1.5	3
624	Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 262-269.	1.2	3
625	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10â€‰220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. European Journal of Preventive Cardiology, 0, . .	1.8	3
626	Feasible approaches and implementation challenges to atrial fibrillation screening: a qualitative study of stakeholder views in 11 European countries. BMJ Open, 2022, 12, e059156.	1.9	3
627	Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope. Current Therapeutic Research, 1997, 58, 842-850.	1.2	2
628	Internal Low Energy Atrial Cardioversion: Efficacy and Safety in Older Patients with Chronic Persistent Atrial Fibrillation. Journal of the American Geriatrics Society, 2001, 49, 80-84.	2.6	2
629	Clinical and therapeutic implications of troponin elevation in cardiac arrest. American Journal of Cardiology, 2004, 94, 1478.	1.6	2
630	Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial. Europace, 2006, 8, 302-305.	1.7	2

#	Article	IF	Citations
631	Effects of Cardiac Resynchronization Therapy on Diastolic Function: Evaluation by Radionuclide Angiography. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S43-6.	1.2	2
632	Local Amyloidosis as a Possible Component of the Atrial Remodeling Accompanying Trial. Journal of the American College of Cardiology, 2008, 51, 2444-2445.	2.8	2
633	Response:. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1361-1362.	1.2	2
634	Cardiac resynchronization therapy: is systole all that matters?. Europace, 2010, 12, 1209-1210.	1.7	2
635	Peri-operative management of patients taking antithrombotic therapy: need for an integrated proactive approach. International Journal of Clinical Practice, 2011, 65, 236-239.	1.7	2
636	Winning the war, far, in developing countries. Novel anticoagulants as a new weapon against stroke. International Journal of Cardiology, 2012, 154, 336-337.	1.7	2
637	Left ventricular pacing rate lower than expected during manual pacing threshold test in a biventricular defibrillator. Europace, 2013, 15, 826-826.	1.7	2
638	Beat-to-beat variability of P-wave in patients suffering from atrial fibrillation. , 2016, 2016, 770-773.		2
639	Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 973-978.	0.2	2
640	Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial. Revista Portuguesa De Cardiologia, 2018, 37, 973-978.	0.5	2
641	Nationwide survey on the current practice of ventricular tachycardia ablation. Journal of Cardiovascular Medicine, 2019, 20, 597-605.	1.5	2
642	Cardiac resynchronization therapy: need to synchronize patients and device longevities with comorbidities. Europace, 2019, 21, 683-685.	1.7	2
643	Prognostic value of implantable defibrillatorâ€“computed respiratory disturbance index: The DASAP-HF study. Heart Rhythm, 2021, 18, 374-381.	0.7	2
644	Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology, 2021, 62, 152-157.	1.0	2
645	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. Europace, 2023, 25, .	1.7	2
646	Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. Thrombosis and Haemostasis, 2021, , .	3.4	2
647	Atrial fibrillation is related to higher mortality in COVID-19/SARS-CoV-2 pneumonia infection. Cardiology Journal, 2021, 28, 973-975.	1.2	2
648	From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach. European Journal of Internal Medicine, 2020, 77, 27-29.	2.2	2

#	Article	IF	Citations
649	The Practice of Deep Sedation in Electrophysiology and Cardiac Pacing Laboratories: Results of an Italian Survey Promoted by the AIAC (Italian Association of Arrhythmology and Cardiac Pacing). Journal of Clinical Medicine, 2021, 10, 5035.	2.4	2
650	Cardiac resynchronization therapy: variations across Europe in implant rates and types of implanted devices. Journal of Cardiovascular Medicine, 2021, 22, 90-93.	1.5	2
651	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. International Journal of Cardiology, 2022, 346, 19-26.	1.7	2
652	Role of cardiac imaging in patients undergoing catheter ablation of ventricular tachycardia. Journal of Cardiovascular Medicine, 2021, 22, 727-737.	1.5	2
653	Vascular Accesses in Cardiac Stimulation and Electrophysiology: An Italian Survey Promoted by AIAC (Italian Association of Arrhythmias and Cardiac Pacing). Biology, 2022, 11, 265.	2.8	2
654	Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emeryâ€“Dreifuss Muscular Dystrophies: A Systematic Review of the Literature. Biology, 2022, 11, 530.	2.8	2
655	Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation. Journal of Cardiovascular Development and Disease, 2022, 9, 126.	1.6	2
656	Association between implantable defibrillatorâ€detected sleep apnea and atrial fibrillation: the DASAPâ€HF study. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	2
657	Rhythm Control and Increased Risk of Noncardiovascular Death in the Atrial Fibrillation Follow-up Investigation of Rhythm Management Trial. Circulation, 2004, 110, e307-8; author reply e307-8.	1.6	1
658	Rate control in AFFIRM: Considerations about the clinical implications. American Journal of Cardiology, 2004, 94, 1104-1105.	1.6	1
659	Solution to a Crushing Dosage Problem?. Pediatrics, 2004, 113, 1468-1468.	2.1	1
660	P1-72. Heart Rhythm, 2006, 3, S131.	0.7	1
661	Celebrating 50 years of electrical therapies for the heart. Country Review Ukraine, 2007, 9, I1-I2.	0.8	1
662	Case of the month by the EHRA Education committee: exercise-related arrhythmias. Europace, 2008, 10, 235-237.	1.7	1
663	Atrial fibrillation ablation: beyond electro-mechanical matters. European Heart Journal, 2008, 29, 2818-2819.	2.2	1
664	Effect of ECG filtering on time domain analysis of the P-wave. , 2008, , .		1
665	The QRS interval in patients treated with resynchronization therapy: which value?. European Journal of Heart Failure, 2009, 11, 635-637.	7.1	1
666	P-wave characteristics after electrical external cardioversion: Predictive indexes of relapse. , 2010, 2010, 3442-5.		1

#	Article	IF	Citations
667	La tachicardiomiopatia: una revisione della letteratura. Italian Journal of Medicine, 2010, 4, 92-98.	0.3	1
668	Pacing-induced torsades de pointes after the short-long-short sequence in a patient with a biventricular defibrillator: What is the mechanism?. Heart Rhythm, 2014, 11, 728-731.	0.7	1
669	Cardiac Resynchronization Therapy: State of the Art. Cardiac Electrophysiology Clinics, 2015, 7, xvii-xviii.	1.7	1
670	The Impact of Diabetes and Comorbidities on the Outcome of Heart Failure Patients Treated With Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	1
671	Switching among Equivalents in Chronic Cardiovascular Therapies: â€˜Real Worldâ€™ Data from Italy. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 63-69.	2.5	1
672	Electrical treatment of atrial arrhythmias in heart failure patients implanted with a dual defibrillator CRT device. Results from the TRADE-HF study. International Journal of Cardiology, 2017, 236, 181-186.	1.7	1
673	Letter responding to Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Societad Latinoamericana de Estimulation Cardiaca y Electrofisiologia (SOLAECE)â€"Authorsâ€™ reply. Europace, 2018, 20, 893-894.	1.7	1
674	Degree of left ventricular dilatation at endâ€diastole: Correlation and prognostic utility of quantitative volumes by 2Dâ€echocardiography versus linear dimensions in patients with asymptomatic aortic regurgitation. Echocardiography, 2020, 37, 1336-1344.	0.9	1
675	Effect on mortality of different routes of administration and loading dose of aspirin in patients with ST-segment elevation acute myocardial infarction treated with primary angioplasty. Coronary Artery Disease, 2020, 31, 348-353.	0.7	1
676	Trans-catheter valve implantation and patient outcomes: Focus on the kidney. European Journal of Internal Medicine, 2021, 83, 88-89.	2.2	1
677	Prevention of longâ€lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers. International Journal of Clinical Practice, 2021, 75, e13820.	1.7	1
678	Grey zones in the practice of permanent cardiac pacing: The case of preventive pacing for improving rhythm control in atrial fibrillation. International Journal of Clinical Practice, 2021, 75, e13728.	1.7	1
679	Permanent Atrial Fibrillation as the Terminal Stage of a Chronic Disease: Palliative Care Needs to be Considered in Selected Patients with Markedly Impaired Quality of Life. Cardiology, 2021, 146, 397-399.	1.4	1
680	Infective endocarditis with perivalvular abscess complicated by septic embolization with acute ST-segment elevation myocardial infarction and peripheral ischemia. IJC Heart and Vasculature, 2021, 32, 100711.	1.1	1
681	Procedural complications in patients undergoing catheter ablation for atrial fibrillation: let's talk about sex. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 427-428.	4.0	1
682	OUP accepted manuscript. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	1
683	Case Report: Free-Floating Intracoronary Thrombus: Who Is the Convict?. Frontiers in Oncology, 2022, 12, 825711.	2.8	1
684	684â€ƒCardiac troponins and adverse outcomes in European patients with atrial fibrillation: a report from the ESC-EHRA EORP atrial fibrillation general long-term registry. European Heart Journal Supplements, 2021, 23, .	0.1	1

#	Article	IF	Citations
685	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an <scp>individual patient data metaâ€analysis</scp> of <scp>COMPANION</scp> and <scp>CAREâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1091-1093.	7.1	1
686	Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator. International Journal of Cardiology, 2004, 97, 143-144.	1.7	0
687	Cost-Effectiveness of Implantable Cardioverter-Defibrillators. , 0, , 263-279.		0
688	Role of severe functional mitral regurgitation in predicting electrical remodeling in idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 691-695.	1.5	0
689	Case of polymorphic ventricular tachycardia after stroke necessitating defibrillation. Europace, 2007, 10, 77-78.	1.7	0
690	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 243-246.	2.2	0
691	Potential of Medical Treatment, Device Therapy, and Conventional Surgery in Patients Referred for Heart Transplantation. Journal of Cardiac Surgery, 2007, 22, 456-458.	0.7	0
692	Letter by Boriani et al Regarding Article, â€œDeath Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Studyâ€• Circulation, 2008, 118, e515; author reply e516.	1.6	0
693	How to assess the efficacy of catheter ablation of atrial fibrillation?. European Heart Journal, 2008, 29, 2183-2184.	2.2	0
694	Reply to Reader's Comment: â€œElectrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!â€•by Mont et al. American Journal of Cardiology, 2009, 103, 1625-1626.	1.6	0
695	Prediction of Life-threatening Ventricular Tachyarrhythmias and Death in Patients with Previous Myocardial Infarction by Left Ventricular Longitudinal Strain Analysis. Heart Lung and Circulation, 2009, 18, S46.	0.4	0
696	A subcutaneous ICDâ€”preliminary results. Nature Reviews Cardiology, 2010, 7, 543-544.	13.7	0
697	'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation. Heart, 2010, 96, 1605-1606.	2.9	0
698	Delayed asymptomatic migration of an implantable cardioverter-defibrillator lead to the costophrenic angle. Europace, 2010, 12, 1126-1126.	1.7	0
699	Response:. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 389-390.	1.2	0
700	The Challenge of Preventing Stroke in Elderly Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 31-33.	1.7	0
701	Identifying the patient who FADES away prior to appropriate ICD intervention. Heart, 2012, 98, 833-834.	2.9	0
702	Atrial Fibrillation. Chest, 2012, 141, 290-292.	0.8	0

#	Article	IF	Citations
703	Response to the Letter from Dr Bertini. Europace, 2013, 15, 613-614.	1.7	0
704	Against all odds: Targeted pacing site for resynchronization therapy by venoplasty and active fixation lead. Indian Heart Journal, 2015, 67, 574-576.	0.5	0
705	Oral loading of propafenone: restoring its role before restoring rhythm. Europace, 2017, 19, 1903-1903.	1.7	0
706	Establishing and Managing a Device Clinic and Database. , 2017, , 1191-1200.		0
707	In Memoriam Luigi Padeletti: an Italian Scientist, an Italian Maestro, an Italian Friend. Europace, 2018, 20, 1063-1064.	1.7	0
708	Pacemaker-detected severe sleep apnoea predicts new-onset atrial fibrillation: Authorâ€™s reply. Europace, 2018, 20, 2047-2048.	1.7	0
709	Cancer and atrial fibrillation. Author's reply. European Journal of Internal Medicine, 2019, 62, e24-e25.	2.2	0
710	Cardiac arrest: The need for integrated multi-disciplinary actions for a continuum of care both in acute and at long-term. European Journal of Internal Medicine, 2020, 74, 37-39.	2.2	0
711	A giant right coronary artero-venous fistula revealed by an integrated multimodality imaging approach. Internal and Emergency Medicine, 2020, 15, 1331-1332.	2.0	0
712	Infection of Cardiac Implantable Electrical Devices: An Emerging Epidemiological Issue. , 2020, , 1-16.		0
713	Prevention of Device Infection: Procedural Aspects, Drugs, and Preventive Tools. , 2020, , 177-208.		0
714	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Management and Outcome. Journal of Atrial Fibrillation, 2013, 5, 748.	0.5	0
715	Estimate and reporting of longevity for cardiac implantable electronic devices: a proposal for standardized criteria. Expert Review of Medical Devices, 2021, 18, 1203-1208.	2.8	0
716	Solution to a Crushing Dosage Problem?. Pediatrics, 2004, 113, 1468-1468.	2.1	0
717	Ten-year follow-up of cardiac resynchronization therapy patients with non-ischemic dilated cardiomyopathy assessed by radionuclide angiography: a single-center cohort study. Journal of Interventional Cardiac Electrophysiology, 2022, , .	1.3	0
718	444â€ƒEpidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. European Heart Journal Supplements, 2021, 23, .	0.1	0
719	Implantable cardioverterâ€defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the â€˜real worldâ€™?. European Journal of Heart Failure, 2022, 24, 1223-1226.	7.1	0